Regulation & Industry Affairs

SHERIDAN, WYOMING – July 1, 2025 – A late surge of acquisitions in June has reenergized pharmaceutical M&A activity, with six major deals announced that propelled first-half 2025 totals to 32 transactions across the industry. This burst of dealmaking, highlighted by BioNTech’s $1.25 billion acquisition of CureVac and Eli Lilly’s $1.3 billion buyout of Verve Therapeutics, has analysts optimistic that the sector’s cautious stance may finally be easing.

Resilient M&A Amid Regulatory Uncertainty

SHERIDAN, WYOMING – July 1, 2025 – A groundbreaking collaboration that delivered a custom-made CRISPR therapy to a nine-month-old patient with CPS1 deficiency has ignited optimism that ultrarare diseases could soon be addressed on a broader scale, thanks to advances in delivery systems, precision gene editing, and regulatory pathways.

SHERIDAN, WYOMING – July 1, 2025 – A wave of pivotal FDA decisions in June 2025 is reshaping key segments of the pharmaceutical landscape, with new approvals spanning respiratory syncytial virus (RSV) vaccines, advanced cancer treatments, and the first-ever antiviral for acute hepatitis C. These regulatory moves not only expand therapeutic options for patients but also set the stage for intensified competition in critical markets, underscoring strategic opportunities for companies across the biopharmaceutical sector.

SHERIDAN, WYOMING – June 12, 2025 – In a strategic move signaling regulatory reform and modernization, FDA Commissioner Marty Makary and CBER Director Vinay Prasad have outlined a new four-year roadmap for the agency in The Journal of the American Medical Association (JAMA). Their article, “Priorities for a New FDA,” introduces a reform-focused agenda that emphasizes accelerated drug approval timelines, generative AI implementation, and a renewed focus on cost transparency and public health outcomes.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced an encouraging update on its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx), following discussion by the FDA’s Oncologic Drugs Advisory Committee (ODAC). The combination therapy demonstrated a significant 41% reduction in the risk of death in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not candidates for autologous stem cell transplant.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has announced a major leadership transition, with Executive Vice President and Chief Financial Officer Dan Brennan set to retire after nearly three decades with the company. Brennan will step down from the CFO role at the end of June and continue serving as a senior advisor through early October 2025, as Jon Monson, currently Senior Vice President of Investor Relations, is appointed to succeed him.

Leadership Change Marks a Strategic Financial Milestone

SHERIDAN, WYOMING – May 6, 2025 – Marriott International has announced its agreement to acquire citizenM, a distinctive and tech-forward lifestyle brand, in a move that significantly strengthens its global presence in the select-service and lifestyle hotel segment. This $355 million acquisition underscores Marriott's continued focus on delivering diversified, design-forward lodging experiences and positions the company to tap into evolving traveler preferences and unlock new revenue streams.

Strategic Expansion of Lifestyle Offerings

SHERIDAN, WYOMING – May 6, 2025 – U.S. consumer confidence tumbled for the fifth consecutive month in April, according to the latest data from The Conference Board, highlighting growing economic anxiety and a potential warning sign for future business and labor market conditions. The Consumer Confidence Index® fell to 86.0—its lowest level since the early days of the COVID-19 pandemic—driven by a significant deterioration in consumers' outlook on business conditions, employment, and personal finances.

Expectations Plummet to Recessionary Levels

SHERIDAN, WYOMING – May 6, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced key updates to its Supervisory Board composition and committee leadership ahead of its Annual General Meeting (AGM) scheduled for May 8, 2025. The adjustments, prompted by recent executive developments, aim to reinforce strategic governance while maintaining alignment with shareholder interests and regulatory best practices.

Strategic Governance Realignment Following CEO Nomination

SHERIDAN, WYOMING – May 5, 2025 – 3M (NYSE: MMM) has announced it will hold its first-quarter 2025 earnings conference call on Tuesday, April 22, 2025, at 8 a.m. CT, providing a critical update on its financial performance and ongoing strategic initiatives to global investors and stakeholders.